Angioedema risk of thrombolytics: an integrated assessment using disproportionality analysis of the USFDA adverse event reporting system, case reviews and meta-analysis

This analysis suggests a consistent association increased angioedema risk with thrombolytic-RAAS-i combination therapy. Findings underscore the importance of careful risk assessment and monitoring in patients receiving RAAS-i therapy, especially those on ACEIs.